公开(公告)号：US20210179703A1

公开(公告)日：2021-06-17

申请号：US17164384

申请日：2021-02-01

Applicant: Janssen Biotech, Inc.

Inventor： Dennis Fitzgerald ,  Jay Siegel ,  Newman Yeilding

IPC: C07K16/24 ,  A61K9/00 ,  G01N33/00 ,  A61P17/06 ,  A61K31/519 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US20250129149A1

公开(公告)日：2025-04-24

申请号：US18945730

申请日：2024-11-13

Applicant: Janssen Biotech, Inc.

Inventor： Dennis Fitzgerald ,  Jay Siegel ,  Newman Yeilding

IPC: C07K16/24 ,  A61K9/00 ,  A61K31/519 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/22 ,  A61K47/26 ,  A61P17/06 ,  C07K16/28 ,  G01N33/00

Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US11208474B2

公开(公告)日：2021-12-28

申请号：US15813767

申请日：2017-11-15

Applicant: Janssen Biotech, Inc.

Inventor： Dennis Fitzgerald ,  Newman Yeilding ,  Jay Siegel

IPC: A61K39/395 ,  C07K16/24 ,  A61K9/00 ,  G01N33/00 ,  A61P17/06 ,  A61K31/519 ,  A61K45/06 ,  C07K16/28 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00

Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US20180134784A1

公开(公告)日：2018-05-17

申请号：US15813767

申请日：2017-11-15

Applicant: Janssen Biotech, Inc.

Inventor： Dennis Fitzgerald ,  Newman Yielding ,  Jay Siegel

IPC: C07K16/24 ,  A61K47/26 ,  A61K47/22 ,  A61K39/395 ,  A61K45/06 ,  A61K31/519 ,  C07K16/28 ,  A61P17/06

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61K31/519 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/545 ,  A61P17/06 ,  C07K16/28 ,  C07K16/2887 ,  C07K2317/21 ,  G01N33/00

Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.